Ovid Therapeutics, Inc. (OVID)
2.40
-0.10
(-3.81%)
USD |
NASDAQ |
Sep 25, 16:00
2.41
+0.01
(+0.42%)
After-Hours: 19:59
Ovid Therapeutics Price to Book Value : 2.113 for Sept. 25, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| September 25, 2026 | 2.113 |
| September 24, 2026 | 2.196 |
| September 23, 2026 | 2.262 |
| September 22, 2026 | 2.430 |
| September 21, 2026 | 2.386 |
| September 18, 2026 | 2.368 |
| September 17, 2026 | 2.377 |
| September 16, 2026 | 2.359 |
| September 15, 2026 | 2.386 |
| September 14, 2026 | 2.412 |
| September 11, 2026 | 2.368 |
| September 10, 2026 | 2.315 |
| September 09, 2026 | 2.377 |
| September 08, 2026 | 2.421 |
| September 04, 2026 | 2.465 |
| September 03, 2026 | 2.447 |
| September 02, 2026 | 2.386 |
| September 01, 2026 | 2.430 |
| August 31, 2026 | 2.350 |
| August 28, 2026 | 2.465 |
| August 27, 2026 | 2.579 |
| August 26, 2026 | 2.535 |
| August 25, 2026 | 2.562 |
| August 24, 2026 | 2.482 |
| August 21, 2026 | 2.465 |
| Date | Value |
|---|---|
| August 20, 2026 | 2.412 |
| August 19, 2026 | 2.579 |
| August 18, 2026 | 2.500 |
| August 17, 2026 | 2.544 |
| August 14, 2026 | 2.491 |
| August 13, 2026 | 2.465 |
| August 12, 2026 | 2.306 |
| August 11, 2026 | 2.271 |
| August 10, 2026 | 2.306 |
| August 07, 2026 | 2.315 |
| August 06, 2026 | 2.333 |
| August 05, 2026 | 2.306 |
| August 04, 2026 | 2.236 |
| August 03, 2026 | 2.051 |
| July 31, 2026 | 1.954 |
| July 30, 2026 | 2.086 |
| July 29, 2026 | 2.016 |
| July 28, 2026 | 2.077 |
| July 27, 2026 | 2.069 |
| July 24, 2026 | 2.051 |
| July 23, 2026 | 2.113 |
| July 22, 2026 | 2.095 |
| July 21, 2026 | 2.121 |
| July 20, 2026 | 2.029 |
| July 17, 2026 | 2.148 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.724 |
| Alnylam Pharmaceuticals, Inc. | 25.28 |
| Anika Therapeutics, Inc. | 1.986 |
| Savara, Inc. | 7.149 |
| Vericel Corp. | 5.491 |
Price to Book Value Related Metrics
| PS Ratio | 184.36 |
| Price | 2.40 |
| Earnings Yield | -10.56% |
| Market Cap | 443.41M |